1 / 16

Molecular Epidemiology and Susceptibility to Malaria Infection

Molecular Epidemiology and Susceptibility to Malaria Infection. Douglas Jay Perkins, Ph.D. University of Pittsburgh Graduate School of Public Health Department of Infectious Diseases and Microbiology Centers for Disease Control and Prevention Division of Parasitic Diseases-Immunology Branch

fiorello
Download Presentation

Molecular Epidemiology and Susceptibility to Malaria Infection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Molecular Epidemiology and Susceptibilityto Malaria Infection Douglas Jay Perkins, Ph.D. University of Pittsburgh Graduate School of Public Health Department of Infectious Diseases and Microbiology Centers for Disease Control and Prevention Division of Parasitic Diseases-Immunology Branch Molecular Vaccine Section, Atlanta, GA

  2. Merozoites Sporozoites Male and female gametocytes Sporozoites Malaria Transmission Cycle Pre-erythrocytic Asymptomatic Erythrocytic Clinical symptoms

  3. Malaria in Humans • Four species of genus Plasmodium infect humans: P. falciparum, P. vivax, P. ovale, and P. malariae • Transmitted by female Anopheline mosquito • 300-500 million clinical cases per year

  4. Populations at Risk • Infants, young children, and pregnant women in malaria endemic regions • Greater than 3 million deaths (primarily in children less than 5 y/o due to non-immune status) • Non-immune individuals traveling through and/or living in malaria endemic regions • 35 million non-immune individuals travel through malaria endemic regions every year

  5. Clinical Features of P. falciparum • P. falciparum can cause severe malaria:-hyperparasitemia -severe anemia -hypoglycemia-respiratory distress-cerebral malaria • Molecular determinants that regulate mild versus severe disease largely unknown

  6. Current Situation: Major International Health Problem • Rapidly expanding number of clinical cases each year • Growing problem of antimalarial drug resistance with few novel therapeutics available • Lack of an effective vaccine

  7. Potential Solutions • Gain an understand of the genetic and immunologic basis of protective immunity • Identify novel targets for therapeutic intervention • Determine reliable markers for measuring protection and pathogenesis for use in pharmacologic and/or vaccine trials

  8. Genetic Susceptibilityto Malaria • At least 10,000 years of “pressure” on the human genome from the malaria parasite • In 1948 J.B.S. Haldane suggested that the high frequency of thalassemia in Mediterranean populations might confer a heterozygote advantage against malaria • Thalassemias are defects in synthesis of either a- or b-globin chains of hemoglobin (hemoglobin adult = a2b2) • Mechanism of protection may be related to increased binding of antibodies and/or increased retention of fetal hemoglobin

  9. Sickle Cell Gene and Resistanceto Malaria • Over 400 abnormal hemoglobins but only three reach polymorphic frequencies (S, C, & E) • Homozygous state (SS) = sickle cell disease • Heterozygous state (SC) = protection from malaria • Mechanism unknown but red blood cells from (SC) individuals have reduced parasite growth and impaired invasion under low O2 tension • In addition to red cell abnormalities, there are many other genetic changes……..

  10. Host Response Genes and Susceptibility to Malaria • In 1993 Murphy compared sequences of human and rodent genes and found greater variability among host defense genes • Polymorphisms in cytokines genes (e.g. TNF-a) and effector molecules (e.g. nitric oxide, NO) are now being investigated • Study of genetic variation may utilize several types of DNA markers to analyze candidate susceptibility genes Single base pair variations = SNPs Microsatellite or variable number tandem repeats (VNTRs)

  11. Overview Part 1. NOS2 (G –954C) in Gabonese Children with Severe Malarial Anemia Part 2. NOS2 (G –954C) in Tanzanian Children with Cerebral Malaria Part 3. NOS2 (G –954C) in Kenyan Children with Severe Malarial Anemia

  12. Nitric Oxide Biosynthesis NOS L-Arginine L-Citrulline + NO L-NMMA Aminoguanidine NO2- NO3- NOS Enzyme Assay Cellular Lysate [14C]L-Arg remains Co-factors [14C]L-Arg [14C]L-Cit [14C]L-Cit flows through Cation Exchange Column

  13. Nitric Oxide Synthase eNOS & nNOS NOS3 NOS1 iNOS NOS2 Constitutive Expression Inducible Expression - Ca2+- and Calmodulin- Dependent - Ca2+- and Calmodulin- Independent NO Synthesis for Normal Physiologic Function NO Synthesis in the Setting of Inflammation

  14. Nitric Oxide: Previous Observations in Malaria • Nitric oxide production is anti-plasmodial in vitro and in vivo-(Oswald et al.,Comp Biochem Physiol Pharmacol Toxicol Endocrino, 1994; 108:11-18) • Elevated NO metabolites are associated with accelerated clinical cure and increased parasitologic clearance in Gabonese adults and children-(Kremsner et al., Trans R Soc Trop Med Hyg, 1996; 90: 44-47) • NO appears protective against malaria

  15. IFN-g IL-12 IL-10 Lymphocyte TNF-a TGF-b1 IFN-a Parasitic Products NOS2 NO N = O S Enz Fe N = O S Model of NO Production in Malaria Monocyte PRBC PRBC Monocyte/Macrophage

  16. Hypothesis Increased capacity of the host to generate nitric oxide is protective against severe malaria

More Related